TEVA-DAPAGLIFLOZIN TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

DAPAGLIFLOZIN

Disponible desde:

TEVA CANADA LIMITED

Código ATC:

A10BK01

Designación común internacional (DCI):

DAPAGLIFLOZIN

Dosis:

10MG

formulario farmacéutico:

TABLET

Composición:

DAPAGLIFLOZIN 10MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Resumen del producto:

Active ingredient group (AIG) number: 0156370002; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2023-05-15

Ficha técnica

_Teva-Dapagliflozin Page 1 of 72_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-DAPAGLIFLOZIN
dapagliflozin tablets
Tablets, 5 mg and 10 mg, Oral
ATC Code: A10BK01
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario M1B 2K9
Canada
Date of Initial Authorization:
DEC 21, 2021
Submission Control No: 246884
_Teva-Dapagliflozin Page 2 of 72_
RECENT MAJOR LABEL CHANGES
NOT APPLICABLE.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.......................................................................................................
2
TABLE OF CONTENTS
.........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................................
4
1
INDICATIONS
........................................................................................................................
4
1.1
Pediatrics
............................................................................................................................
4
1.2
Geriatrics
............................................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
......................................................................
5
4
DOSAGE AND ADMINISTRATION
...........................................................................................
5
4.1
Dosing Considerations
........................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.................................................................. 5
4.5
Missed Dose
..................................